Tiny antibody component could treat or prevent SARS-CoV-2

Modesto Morganelli
Settembre 16, 2020

Researcher John Mellors of the University of Pittsburgh, USA, associated with this study, said, "AB8 not only has the ability to treat Covid-19 but also can help people avoid infection".

These are man-made antibodies that act like human antibodies in the immune system. It was found by "fishing" in a pool of more than 100 billion potential candidates targeting the SARS-CoV-2 spike protein.

Ab8 also does not bind to human cells, which is a sign that it won't cause negative side effects in patients. They have found this drug to be largely effective in the prevention and treatment of infections.

Scientists at the University of Pittsburgh School of Medicine (UPMC) have isolated an antibody, dubbed Ab8, that is 10x smaller than a full-sized antibody used in drugs and completely neutralizes the SARS-CoV-2 virus.

The researchers, along with scientists at the University of North Carolina at Chapel Hill, University of Saskatchewan, the University of Texas Medical Branch at Galveston and the University of British Columbia, will be evaluating Ab8 and its efficacy.

He added that larger antibodies have been effective against other infectious diseases, giving the world a hope that they could also cure and prevent COVID-19 infections.

The researchers said that the medicine could be administered as an inhaled drug or intradermally because of its small size. There are good reasons to be excited about this new development - RECOVERY will provide a robust assessment of the effect of this lab-manufactured monoclonal antibody combination treatment in hospitalized patients. "REGN-COV2 was specifically designed by Regeneron scientists to target the virus that causes COVID-19". The antibody against Hendra and Nipah viruses has been evaluated in humans and approved for clinical use on a compassionate basis in Australia.

Convalescent plasma - blood plasma taken from patients who have recovered from SARS-CoV-2 and therefore contains anti-SARS-CoV-2 antibodies - is now being tested in clinical trials as a treatment for those battling COVID-19. Due to the smaller size, it can easily diffuse into the tissues and effectively neutralizes the virus. Also, this molecule helps prevent infection in hamsters. The rodents that were treated with the drug had significantly less (10-fold less of the amount) of infectious virus compared to those that were not treated.

"The pandemic is a global challenge facing humanity, but biomedical science and human ingenuity are likely to overcome it", said Mellors, also Distinguished Professor of Medicine, who holds the Endowed Chair for Global Elimination of HIV and AIDS at Pitt.

Funds for the research comes from the National Institutes of Health grants, and UPMC, the Burroughs Wellcome Fund.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE